Evidence Base & Guidance
Synthesised from Cochrane, NICE, NICE CG57, AAD Pediatric Guideline 2026, MHRA, FDA, European Medicines Agency, SAHPRA, National Eczema Society, National Eczema Association, HOME Initiative and other members of MOC-evidence-base-and-guidance. Infranodus clusters 0 and 4 (cochrane, academy; nice).
Overview
The verdicts in this vault rest on a layered evidence system. At the top are systematic reviews, above all those of Cochrane Skin. Its reviews of emollients, topical steroids, oil supplements, probiotics and Chinese herbs decide most comparisons between Track A (home and herbal care) and Track B (prescribed care). Next come clinical guidelines that turn evidence into recommendations: NICE CG57 in England and Wales, the AAD Pediatric Guideline 2026 in the US, and South African Eczema Guidance. Narrower guidelines such as NICE NG190 (infected eczema) and NICE NG153 (impetigo) cover specific situations. Guideline bodies grade evidence with GRADE, and the HOME Initiative standardises the outcomes trials measure, so that reviews can pool them.
Beside these sit the regulators, who decide which products may be sold, at what age and with what warnings. They are the MHRA (UK), FDA (US), European Medicines Agency (EU) and SAHPRA (South Africa). Their decisions often differ, so a cream licensed for a 2-year-old in one country may be off-label or unavailable in another. Professional bodies and charities then translate all this for families. The British Association of Dermatologists and American Academy of Dermatology publish leaflets and guidelines. The National Eczema Society (UK) and National Eczema Association (US) run helplines, factsheets and product marks.
The system has two weaknesses that matter for toddlers. First, it is ageing in places. Most recommendations in NICE CG57 are still labelled [2007], so much of its evidence base is close to 20 years old, while the AAD’s 2026 paediatric guideline is a fresh GRADE review. Second, few trials enrolled only 1–4-year-olds, so most guideline statements for toddlers are extrapolated from mixed child or adult data. The practical end of the system is the Stepped Care Approach and its top rung, When to Refer.
Key Entities
Cochrane
Cochrane is an international network of systematic reviewers. Its dermatology arm, Cochrane Skin, was founded in 1997 by Hywel Williams at Nottingham’s Centre of Evidence-Based Dermatology. In 2023 its editorial base moved to Créteil, Paris, after UK funding ended, and it is still active in 2026. For this vault it is the top evidence tier. Its reviews found that moisturisers reduce severity and flares (2017, 77 RCTs) and that topical steroids show a clear potency gradient, with proactive use cutting flares (2022, 104 RCTs). They also found no benefit from evening primrose and borage oil (2013), probiotics (2018), Chinese herbs (2013), oral antihistamines (2019) or house-dust-mite avoidance (2015).
NICE and NICE CG57
NICE is England’s health guidance body. Its core eczema product, CG57 Atopic eczema in under 12s (2007, last updated September 2025), sets diagnosis by adapted UK Working Party Criteria, severity grading, and the Stepped Care Approach. Under that approach emollients are always used, and steroid potency is matched to severity and body site. Quality standard QS44 makes this measurable, for example 250–500 g of unperfumed emollient a week. NICE spreads its eczema guidance across several products. TA82 limits calcineurin inhibitors to second line. NICE NG190 (2021) advises no routine antibiotics for infected eczema in a well child, and fusidic acid or flucloxacillin for 5–7 days if needed. NICE NG153 (2020) puts hydrogen peroxide 1% cream first for localised impetigo.
AAD Pediatric Guideline 2026 and the American Academy of Dermatology
Published in JAAD in April 2026, this is the AAD’s first guideline written only for under-18s. It replaces the 2014 four-part guideline. It makes 27 GRADE-rated recommendations. They are strong for moisturisers (9 RCTs, 1,260 children), topical steroids and calcineurin inhibitors, and they cover four new non-steroid creams and Dupilumab from 6 months. Only US-available treatments were in scope, so herbal products were not assessed. Beyond guidelines, the AAD also publishes parent pages on Bleach Baths and Soak and Seal.
MHRA
The MHRA is the UK regulator of medicines and devices. It has issued three warnings central to toddler eczema care: Aqueous Cream irritancy, Emollient Fire Risk (with the National Fire Chiefs Council, including paraffin-free products), and steroid-spiked “herbal” creams (Adulterated Herbal Creams, clobetasol found in 2018). It runs the Traditional Herbal Registration scheme, which checks quality, safety and 30 years of traditional use but needs no proof that a product works. In 2024 it called Topical Steroid Withdrawal “the generally accepted patient-led term”.
FDA and European Medicines Agency
The FDA sets US OTC monographs: Hydrocortisone 0.25–1% and Colloidal Oatmeal are the only actives allowed an eczema-itch claim. It kept the 2006 boxed cancer warning on Topical Calcineurin Inhibitors, and it has licensed Crisaborole, Ruxolitinib Cream, Tapinarof Cream and Roflumilast Cream for young children. The EMA licenses EU-wide through the CHMP, with paediatric study plans agreed by its Paediatric Committee. EU labels are often narrower. Dupilumab from 6 months is licensed for severe disease only, ruxolitinib cream for adults only, and the crisaborole licence was withdrawn in 2022. The vault records the two regulators as in conflict on several products.
SAHPRA and South African Eczema Guidance
SAHPRA replaced the Medicines Control Council in 2018. It registers calcineurin inhibitors and registers dupilumab for eczema only from age 6, so toddler use in South Africa is off-label. It is also phasing in control of complementary medicines. South African guidance comes in three layers. A 2008 Dermatological Society of South Africa consensus covered adolescents and adults. The 2014/15 SAMJ all-ages guideline had input from the Allergy Society of South Africa. A 2020 GP and nurse algorithm (Kannenberg) followed, because most patients have no specialist access. It stresses cheap emollients and topical steroids or calcineurin inhibitors within limited public-sector access.
National Eczema Society and National Eczema Association
The UK National Eczema Society (founded 1975, also known as “Eczema UK”) runs a nurse-supported helpline and the factsheets used across this vault. It co-wrote the 2024 UK joint statement on topical steroid withdrawal with the British Association of Dermatologists and the British Dermatological Nursing Group. The US National Eczema Association runs the Seal of Acceptance product mark. It supports bleach baths, describes topical steroid withdrawal as under-recognised, and is more open to complementary care than UK bodies.
HOME Initiative
HOME (founded 2010) is the international consensus group that sets the core outcome set for eczema trials. It chose EASI for signs, POEM for symptoms, IDQoL, CDLQI or DLQI for quality of life, and RECAP or ADCT for long-term control. Because of HOME, trials such as BEE and Eczema Care Online report comparable outcomes that Cochrane can pool.
Stepped Care Approach and When to Refer
CG57’s stepped model uses emollients at every level. Mild eczema gets mild steroids. Moderate eczema gets moderate steroids, calcineurin inhibitors or bandages. Severe eczema gets potent steroids, Phototherapy or systemic therapy. Families with 2–3 flares a month move to weekend maintenance. Referral sits at three speeds. Same-day referral is for suspected Eczema Herpeticum, with systemic Aciclovir started at once. Urgent (2-week) referral is for severe eczema not responding after 1 week, or failed treatment of Infected Eczema. Everything else is routine. These referral rules are [2007] expert consensus, not trial-derived.
Connections Within This Community
NICE CG57 [part-of] NICE NICE CG57 [defines] Stepped Care Approach When to Refer [part-of] Stepped Care Approach NICE NG190 [part-of] NICE CG57 NICE NG153 [relates] NICE NG190 Cochrane [relates] NICE AAD Pediatric Guideline 2026 [relates] NICE CG57 American Academy of Dermatology [part-of] AAD Pediatric Guideline 2026 South African Eczema Guidance [relates] Stepped Care Approach SAHPRA [regulates] South African Eczema Guidance FDA [contradicts] European Medicines Agency European Medicines Agency [relates] MHRA MHRA [regulates] Traditional Herbal Registration National Eczema Society [relates] National Eczema Association British Association of Dermatologists [relates] National Eczema Society
Bridges to Other Communities
- MOC-home-and-herbal-remedies: Cochrane null results (evening primrose oil, probiotics, Chinese herbs) and the MHRA’s Adulterated Herbal Creams warnings and Traditional Herbal Registration decide most Track A verdicts.
- MOC-prescription-anti-inflammatory-therapies: regulators set licence ages for Tacrolimus, Dupilumab and the new non-steroid creams. Their differing labels, and the FDA boxed warning, feed Steroid Phobia and avoidance of calcineurin inhibitors.
- MOC-infection: NICE NG190 and NICE NG153 govern antibiotic choice and stewardship for Impetigo and Infected Eczema.
- MOC-emollients-and-skin-care: NICE and NHS decisions removed Emollient Bath Additives after the BATHE Trial. MHRA warnings cover Aqueous Cream and Emollient Fire Risk.
- MOC-diagnosis-and-differentials: UK Working Party Criteria and HOME instruments (EASI, POEM) link guidance to diagnosis and severity scoring.
- MOC-parent-experience-and-outcomes: charities’ factsheets and helplines, and NICE’s emphasis on education, connect to Eczema Education Programmes and Written Eczema Action Plan.
- Infranodus gaps: the strongest structural gap is
cochrane↔nice. Review evidence and guideline recommendations are discussed in partly separate parts of the vault, withdefinition,soakanddroolas bridge concepts.
Open Questions
- guidelines-questions · guidelines-conflicts
- guideline-currency-questions · guideline-currency-conflicts
- guidance-registries-questions · guidance-registries-conflicts
- organisations-questions · organisations-conflicts
- key-trials-questions
- referral-south-africa-questions · referral-south-africa-conflicts
- remedy-regulation-questions · remedy-regulation-conflicts
- Gap-derived (
cochrane↔nice): Which [2007] recommendations in NICE CG57 conflict with Cochrane reviews published since, such as once-daily steroid use, proactive weekend therapy or bath additives, and when will NICE review them? - Gap-derived: With EMA, FDA, MHRA and SAHPRA setting different age limits for the same drugs, how do guidelines advise clinicians treating a 2-year-old where a drug is licensed in one jurisdiction but not another?